Literature DB >> 6262248

Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis.

Y Sato, K Izumiya, H Sato, J L Cowell, C R Manclark.   

Abstract

Gamma globulins were obtained from rabbits hyperimmunized with the filamentous hemagglutinin (FHA) or the leukocytosis-promoting factor hemagglutinin (LPF.HA) of Bordetella pertussis. Double immunodiffusion analyses showed the antibodies to be highly specific for the homologous antigen. Intraperitoneal injection of anti-FHA or anti-LPF.HA into 10-day-old ICR mice 30 min before aerosol challenge with B. pertussis protected the mice from disease as evidenced by survival and a normal rate of gain in body weight. Both anti-LPF.HA and anti-FHA enhanced the clearance of B. pertussis from the lung and prevented leukocytosis which normally occurs after aerosol infection of mice with B. pertussis. Anti-LPF.HA, but not anti-FHA, neutralized the leukocytosis-promoting and histamine-sensitizing activities of LPF.HA when incubated with the purified protein in vitro. Anti-FHA, but not anti-LPF.HA, prevented the attachment of B. pertussis to mammalian cells (HeLa and Vero) in culture.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6262248      PMCID: PMC351446          DOI: 10.1128/iai.31.3.1223-1231.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Type-specific immunity against intracerebral pertussis infection in mice.

Authors:  N W PRESTON; P EVANS
Journal:  Nature       Date:  1963-02-02       Impact factor: 49.962

2.  Polymorphonuclear leukocyte-inhibitory factor of Bordetella pertussis. I. Extraction and partial purification of phagocytosis- and chemotaxis-inhibitory activities.

Authors:  S Utsumi; S Sonoda; T Imagawa; M Kanoh
Journal:  Biken J       Date:  1978-12

3.  Resistance of Bordetella pertussis phase I to mucociliary clearance by rabbit tracheal mucous membrane.

Authors:  T Matsuyama
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226

4.  Isolation of the lymphocytosis promoting factor-haemagglutinin of Bordetella pertussis by affinity chromatography.

Authors:  L I Irons; A P MacLennan
Journal:  Biochim Biophys Acta       Date:  1979-09-29

5.  Biological properties of islets-activating protein (IAP) purified from the culture medium of Bordetella pertussis.

Authors:  M Yajima; K Hosoda; Y Kanbayashi; T Nakamura; I Takahashi; M Ui
Journal:  J Biochem       Date:  1978-01       Impact factor: 3.387

6.  Separation and characterization of two distinct hemagglutinins contained in purified leukocytosis-promoting factor from Bordetella pertussis.

Authors:  H Arai; Y Sato
Journal:  Biochim Biophys Acta       Date:  1976-10-22

7.  Fimbrial hemagglutinin in stationary and shake cultures of Bordetella pertussis.

Authors:  H Arai; J J Munoz
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

8.  Mouse or man? Which are pertussis vaccines to protect?

Authors:  N W Preston; T N Stanbridge
Journal:  J Hyg (Lond)       Date:  1976-04

9.  Leukocytosis-promoting factor of Bordetella pertussis. 3. Its identity with protective antigen.

Authors:  Y Sato; H Arai; K Suzuki
Journal:  Infect Immun       Date:  1974-05       Impact factor: 3.441

10.  Isolation and properties of the leukocytosis- and lymphocytosis-promoting factor of Bordetella pertussis.

Authors:  S I Morse; J H Morse
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  56 in total

1.  Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis.

Authors:  J W Petersen; P H Ibsen; K Hasløv; I Heron
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

2.  Uptake and intracellular survival of Bordetella pertussis in human macrophages.

Authors:  R L Friedman; K Nordensson; L Wilson; E T Akporiaye; D E Yocum
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 3.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

4.  Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.

Authors:  J L Arciniega; R D Shahin; W N Burnette; T D Bartley; D W Whiteley; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 5.  Pertussis: the disease and new diagnostic methods.

Authors:  R L Friedman
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

6.  Monoclonal antibody-based sandwich enzyme-linked immunosorbent assay for detection of Bordetella pertussis filamentous hemagglutinin.

Authors:  B Gustafsson; P Askelöf
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

7.  Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Authors:  J B Knight; Y Y Huang; S A Halperin; R Anderson; A Morris; A Macmillan; T Jones; D S Burt; G Van Nest; S F Lee
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 8.  The past, present, and future of pertussis. The role of adults in epidemiology and future control.

Authors:  J D Cherry; L J Baraff; E Hewlett
Journal:  West J Med       Date:  1989-03

9.  Serum antibody responses to the outer membrane proteins of Bordetella pertussis.

Authors:  K Redhead
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

10.  Immune response to dimeric subunits of the pertussis toxin B oligomer.

Authors:  S Z Hausman; D L Burns; V C Sickler; C R Manclark
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.